These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34497997)

  • 1. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab.
    Fuchizawa H; Kijima T; Takada-Owada A; Nagashima Y; Okazaki A; Yokoyama M; Nishihara D; Ishida K; Kamai T
    IJU Case Rep; 2021 Sep; 4(5):333-337. PubMed ID: 34497997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
    Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
    In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
    Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
    Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
    Hara T; Furukawa J; Shiraishi Y; Okamura Y; Bando Y; Terakawa T; Harada K; Nakano Y; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):746-752. PubMed ID: 37130778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Sazuka T; Fujimoto A; Sato H; Arai T; Imamura Y; Sakamoto S; Ikeda JI; Ichikawa T
    IJU Case Rep; 2021 Nov; 4(6):355-358. PubMed ID: 34755054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
    Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
    Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
    Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
    Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.
    Kambe T; Yamasaki T; Mine Y; Hagimoto H; Kokubun H; Kubota M; Tsutsumi N; Inoue K; Hara S; Kawakita M
    IJU Case Rep; 2022 May; 5(3):168-171. PubMed ID: 35509785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
    Watanabe K; Sugiyama T; Otsuka A; Miyake H
    Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
    Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
    Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
    [No Abstract]   [Full Text] [Related]  

  • 16. [METASTATIC Mucinous Tubular and Spindle Cell Carcinoma Treated with Nivolumab Successfully : A Case Report].
    Takahashi Y; Numakura K; Aoyama Y; Okada S; Saito T; Muto Y; Koizumi A; Nara T; Chiba S; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Nanjo H; Habuchi T
    Hinyokika Kiyo; 2019 Sep; 65(9):363-367. PubMed ID: 31697878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
    Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
    Front Oncol; 2019; 9():1033. PubMed ID: 31649889
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.
    Okada T; Hamamoto S; Etani T; Naiki T; Sue Y; Banno R; Yamada K; Sakakura T; Yasui T
    Int Cancer Conf J; 2020 Apr; 9(2):88-91. PubMed ID: 32257760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
    Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
    J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma.
    Nakagawa T; Kijima T; Imasato N; Nagoshi A; Nakamura G; Uematsu T; Suzuki I; Nishihara D; Kamai T
    IJU Case Rep; 2022 Jul; 5(4):293-296. PubMed ID: 35795125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.